Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Thoracic Neoplasms 1Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

pembrolizumab 14Docetaxel 7cemiplimab 4avelumab 4Trastuzumab 4Paclitaxel 4fludarabine 3durvalumab 3atezolizumab 3Psychiatric Rehabilitation 3Nivolumab 3Methods 3Gemcitabine 3Fluorouracil 3Early Intervention, Educational 3Cyclophosphamide 3Carboplatin 3Biopsy 3zimberelimab 2poly ICLC 2palbociclib 2belinostat 2amminedichloro(2-methylpyridine)platinum(II) 2Tetrahydrouridine 2Taxes 2Standard of Care 2Specimen Handling 2Sirolimus 2Radiotherapy 2Positron-Emission Tomography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × efineptakin alfa × Breast × Clear all
NCT04054752 2023-11-02

Vaccine Response With NT-I7

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
BreastGastrointestinalGenitourinary

Urinary Bladder Neoplasms, Breast Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡